Ambalal Sarabhai Enterprises
- Market cap
- ₹ 264 Cr.
- P/E
- 19.2x
- P/B
- 1.76x
- 52-week range
- 30.15 – 49.98
- ROE
- 12%
- ROCE
- 12%
- Dividend yield
- 0%
- Debt / equity
- 0.4
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Ambalal Sarabhai Enterprises Limited is an India-based company that is engaged in the business of manufacturing pharmaceuticals and electronics. The Company's segments include Pharmaceuticals and Electronics. Asence Inc., a wholly owned subsidiary of the Company, specializes in the supply of pharmaceutical preparations (finished dosage forms and active pharmaceutical ingredients) to the international markets. Its subsidiary, Sarabhai Chemicals (India) Private Limited, offers products in the oncology, infertility and Uro-gynaec areas. Its wholly owned subsidiary, Suvik Hitek Pvt. Ltd., is engaged in manufacturing pharmaceutical products and marketing generics and veterinary products in the domestic market. Its subsidiary, Systronics (India) Limited, is a manufacturer of analytical and test and measuring instruments, distributing its products across India. Its other subsidiaries include Synbiotics Limited, Asence Pharma Private Limited, and Sarabhai M Chemicals Limited, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Ambalal Sarabhai Enterprises against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.2 against a typical 34.3: cheaper than most peers (1st = cheapest).53rd of 220
- Sales growth+8% against a typical +15.6% from a year earlier.120th of 197
- Profit growth−51.6% against a typical +18.9% from a year earlier.135th of 160
- Share price, 3 months+14.7% against a typical −0.5%.49th of 200
- Size₹ 263.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).111th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 43 | 54 | 41 | 45 | 46 | 65 | 40 | 44 | 52 | 65 | 44 |
| Expenses | 39 | 41 | 50 | 40 | 42 | 47 | 60 | 39 | 44 | 48 | 60 | 39 |
| Operating Profit | 1 | 3 | 5 | 0 | 3 | −1 | 5 | 1 | 0 | 4 | 6 | 5 |
| OPM % | 2.5% | 5.9% | 8.6% | 1.2% | 5.7% | −1.5% | 8.2% | 3.6% | 0.8% | 7.9% | 8.7% | 10.5% |
| Other Income | 3 | 2 | 5 | 2 | 3 | 6 | −5 | 8 | 2 | 2 | 3 | 2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 2 | 8 | 1 | 3 | 3 | −2 | 8 | −0 | 4 | 6 | 5 |
| Tax % | 40% | 34.3% | −8.7% | 59.5% | 15.8% | 23.9% | −86.8% | −3.7% | 1,300% | 16.5% | −4% | 15% |
| Net Profit | 1 | 1 | 9 | 0 | 3 | 2 | −0 | 8 | −1 | 4 | 7 | 4 |
| EPS in Rs | 0.14 | 0.17 | 1.18 | 0.05 | 0.34 | 0.29 | −0.04 | 1.07 | −0.07 | 0.47 | 0.85 | 0.52 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 4%
- 5 Years
- 4%
- 3 Years
- 6%
- TTM
- 5%
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 17%
- TTM
- −24%
- 10 Years
- 22%
- 5 Years
- 9%
- 3 Years
- 20%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 13%
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Ambalal Sarabhai Enterprises | ₹ 35.50 | ₹ 264 Cr. | 19.2x | 1.8x | 12% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.1x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,695.00 | ₹ 23,893 Cr. | 64.3x | 12.6x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 472.00 | ₹ 3,294 Cr. | 54.3x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
Management
- Kartikeya V. Sarabhai
- Executive Chairman of the Board
- Jinal Jaykumar Shah
- Chief Financial Officer
- Disha Mahesh Punjani
- Compliance Officer, Company Secretary
- Chaula M. Shastri
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.